临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2009年
4期
317-319
,共3页
老年精神分裂症%首发%阿立哌唑口崩片%奋乃静%阳性与阴性症状量表%副反应量表
老年精神分裂癥%首髮%阿立哌唑口崩片%奮迺靜%暘性與陰性癥狀量錶%副反應量錶
노년정신분렬증%수발%아립고서구붕편%강내정%양성여음성증상량표%부반응량표
Senile schizophrenia%first-episode%aripiprazole orally distegrating tablets%perphenazine%PANSS%TESS
目的 探讨阿立哌唑口崩片治疗老年期首发精神分裂症患者的临床疗效及安全性. 方法 将94例老年期首发精神分裂症患者随机分为研究组48例和对照组46例,研究组口服阿立哌唑口崩片治疗,对照组口服奋乃静治疗.观察8 w.于治疗前及治疗第2 w、4 w、6 w、8 w末采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应. 结果 治疗8 w末研究组显效率70.8%,总有效率为87.5%;对照组为67.4%、84.8%;两组比较无显著性差异(P＞0.05).两组治疗第2 w末阳性与阴性症状量表总分均较治疗前有显著下降(P均＜0.01),研究组较对照组下降更显著(P均＜0.05);治疗8 w末,总分及阴性因子、认知因子减分率均显著高于对照组(P＜0.05或0.01).对照组不良反应发生率及副反应量表总分均高于研究组(P＜0.05或0.01). 结论 阿立哌唑口崩片治疗老年首发精神分裂症疗效显著,与奋乃静相当,但阿立哌唑起效快,安全性高,依从性高,改善阴性症状、认知功能方面优于奋乃静治疗.
目的 探討阿立哌唑口崩片治療老年期首髮精神分裂癥患者的臨床療效及安全性. 方法 將94例老年期首髮精神分裂癥患者隨機分為研究組48例和對照組46例,研究組口服阿立哌唑口崩片治療,對照組口服奮迺靜治療.觀察8 w.于治療前及治療第2 w、4 w、6 w、8 w末採用暘性與陰性癥狀量錶評定臨床療效,副反應量錶評定不良反應. 結果 治療8 w末研究組顯效率70.8%,總有效率為87.5%;對照組為67.4%、84.8%;兩組比較無顯著性差異(P＞0.05).兩組治療第2 w末暘性與陰性癥狀量錶總分均較治療前有顯著下降(P均＜0.01),研究組較對照組下降更顯著(P均＜0.05);治療8 w末,總分及陰性因子、認知因子減分率均顯著高于對照組(P＜0.05或0.01).對照組不良反應髮生率及副反應量錶總分均高于研究組(P＜0.05或0.01). 結論 阿立哌唑口崩片治療老年首髮精神分裂癥療效顯著,與奮迺靜相噹,但阿立哌唑起效快,安全性高,依從性高,改善陰性癥狀、認知功能方麵優于奮迺靜治療.
목적 탐토아립고서구붕편치료노년기수발정신분렬증환자적림상료효급안전성. 방법 장94례노년기수발정신분렬증환자수궤분위연구조48례화대조조46례,연구조구복아립고서구붕편치료,대조조구복강내정치료.관찰8 w.우치료전급치료제2 w、4 w、6 w、8 w말채용양성여음성증상량표평정림상료효,부반응량표평정불량반응. 결과 치료8 w말연구조현효솔70.8%,총유효솔위87.5%;대조조위67.4%、84.8%;량조비교무현저성차이(P＞0.05).량조치료제2 w말양성여음성증상량표총분균교치료전유현저하강(P균＜0.01),연구조교대조조하강경현저(P균＜0.05);치료8 w말,총분급음성인자、인지인자감분솔균현저고우대조조(P＜0.05혹0.01).대조조불량반응발생솔급부반응량표총분균고우연구조(P＜0.05혹0.01). 결론 아립고서구붕편치료노년수발정신분렬증료효현저,여강내정상당,단아립고서기효쾌,안전성고,의종성고,개선음성증상、인지공능방면우우강내정치료.
Objeceive To explore the efficacy and safety of aripiprazole orally distegrating tablets in senile first-episode schizophrenia.Methods 94 senile first-episode schizophrenics were randomly divided into research group(n=48) took aripiprazole orally distegrating tablets and control group(n=46) did perphenazine for 8 weeks.Clinical efficacies were assessed with the Positive and Negative Syndrome Scale(PANSS) and adverse reactions with the Treatment Emergent Symptom Scale(TESS) before treatment and at the end of the 2nd,4th,6th and 8th week treatment.Results At the end of the 8th week,obvious and total effective rates were 70.8% and 87.5% in the research and 67.4% and 84.8% in the control group, respectively, which showed no significant differences(P>0.05). At the end of the 2nd week, total score of the PANSS of both groups lowered more significantly compared with pretreatment(both P<0.01),that did more significantly in the research than in the control group(P<0.05);at the end of the 8th week,total score and negative and cognitive factor score-decrement rate were all significantly higher in the research than in the control group(P<0.05 or 0.01).Incidences of adverse reactions and total score of the TESS were higher in the control than in the research group(P<0.05 or 0.01).Conclusion Aripiprazole orally distegrating tablets have an evident effect equivalent to perphenazine in senile first-episode schizophrenia,the former take effects faster,have higher safety , better compliance and an advantage in improving negative symptoms and cognitive function over perphenazine.
